1. At a Glance – The Comeback Kid With a Fever?
Market Cap: ₹2,144 Cr
Current Price: ₹350
Book Value: ₹135
Price to Book: 2.60
ROCE: -4.57%
ROE: -4.92%
Debt: ₹22.9 Cr (almost pocket change)
3-Month Return: -10.2%
Welcome to the curious case of Panacea Biotec Ltd, a company that has supplied billions of polio vaccine doses globally… and yet somehow can’t consistently vaccinate its own profit margins.
Q3 FY26 (December 2025 quarter) revenue came in at ₹165.19 Cr, with PAT at ₹3.89 Cr. Yes, profit. A rare sight if you’ve tracked the last few years. Quarterly profit grew 32.6% YoY. But zoom out and the TTM PAT is still negative at ₹-45.31 Cr.
So what are we looking at here?
A turnaround in incubation?
Or just a quarterly sugar rush from other income and one-off awards?
When a company is acknowledged by UN agencies, supplies UNICEF and PAHO, yet trades at negative ROCE, the plot thickens.
Let’s dissect this biotech drama.
2. Introduction – The Polio Fighter That Fights Its Own P&L
Founded in 1984, Panacea Biotec built its reputation in vaccines and pharma formulations. It partnered with global agencies, delivered WHO pre-qualified polio vaccines to 50+ countries, and developed EasyFive and EasySix vaccines.
That sounds like a Nobel Prize nomination resume.
But stock markets don’t reward Nobel resumes. They reward earnings consistency.
And consistency has not exactly been Panacea’s best friend.
Over the last 5 years, sales growth is just 0.55%.
3-year sales CAGR? -5.44%.
TTM profit growth? -134%.
Yet the stock is up 40.5% over 3 years.
How? Hope.
Hope that vaccine contracts convert into stable cash.
Hope that DengiAll (Phase III enrollment completed) becomes a commercial win by 2027.
Hope that regulatory inspections don’t create speed bumps.
So is this a turnaround biotech story… or just cyclical vaccine lottery?
Let’s break it down.
3. Business Model – WTF Do They Even Do?
Panacea operates in two primary segments:
- Vaccines (~56% revenue FY23)
- Formulations (~44% revenue FY23)
Vaccines are their crown jewel. They manufacture:
- Oral Polio Vaccines (tOPV, mOPV1, mOPV3, bOPV)
- Pentavalent vaccine (EasyFive)
- Hexavalent vaccine (EasySix)
They supply UNICEF, PAHO, CMSS, and global agencies.
This isn’t your neighborhood pharmacy
